SU
Therapeutic Areas
Rohto Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RO-1042084 (Dazodalibep) | Sjögren's Syndrome | Phase 3 |
| RO-7011789 (Nidufexor) | Nonalcoholic Steatohepatitis (NASH) | Phase 2b |
| RO-7239361 (BMS-986166) | Moderate to Severe Plaque Psoriasis | Phase 2b |
| RO-7071759 | Dry Eye Disease (DED) | Phase 2 |
| RO-7077169 | Atopic Dermatitis | Phase 2 |